360Dx

2 days ago | 360dx.com | Adam Bonislawski

NEW YORK – Quest Diagnostics addressed on Tuesday the effect of the Trump administration's tariffs on its business, characterizing its exposure as "not zero" but "very manageable."During a conference call following release of the company's Q1 2025 financial results, Quest Chairman and CEO Jim Davis said the company spends around $2 billion annually on reagents, supplies, capital equipment, and service contracts.

3 days ago | 360dx.com | Adam Bonislawski

NEW YORK – Diagnostics firm Genalyte is laying the groundwork for the commercial launch of its Merlin point-of-care clinical analyzer. The San Diego-based firm has completed its submission to the US Food and Drug Administration (FDA) for the device and an initial panel of 37 assays and anticipates receiving 510(k) clearance in the second half of the year, said CEO Ashraf Hanna.

3 days ago | 360dx.com | Adam Bonislawski

NEW YORK – With its recent investment in Munich-based diagnostics firm Recipe, Bruker aims to bring liquid chromatography-free mass spectrometry to the drug testing space.

3 days ago | 360dx.com | Adam Bonislawski

NEW YORK – Diagnostics firm Genalyte is laying the groundwork for the commercial launch of its Merlin point-of-care clinical analyzer. The San Diego-based firm has completed its submission to the US Food and Drug Administration (FDA) for the device and an initial panel of 37 assays and anticipates receiving 510(k) clearance in the second half of the year, said CEO Ashraf Hanna.

6 days ago | 360dx.com | Ben Butkus

NEW YORK – Diagnostics for the Real World, colloquially referred to as DRW, spun out of the University of Cambridge more than 20 years ago. But in many ways, the molecular diagnostics firm resembles a newly minted startup as it prepares for the imminent launch of a retooled version of its rapid, multiplexed, point-of-care molecular diagnostics platform and six new test panels.